Notch1 mutations were recently shown to predict increased risk of chronic lymphocytic leukemia transformation to Richter syndrome:
Development and validation of a Notch1 custom NGS assay for identifying Notch1 mutations in chronic lymphocytic leukemia and other lymphoid malignancies is being discussed at the upcoming 19th European Hematology Association (EHA) Congress. Here is the link to the press release:
Info on the company: OncoMed Pharmaceuticals Inc. is a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells. It will present new data related to the company's anti-Notch1 (OMP-52M51) clinical-stage program.
Photo: a picture of the "Levitated Mass" sculpture I took a few weeks ago at the Los Angeles Museum of Art.